SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3557 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2807KOD selling $287.5M* of stock on unspecified terms: prnewswire.com *AssumingDewDiligence_on_SI-12/2/2019
2806RE: KOD Every so often there is supper-Eylea! Sure... Definitely, Broos infusioMiljenko Zuanic112/2/2019
2805Happy Thanksgiving to all who visit this tread.Miljenko Zuanic111/27/2019
2804By the 2Q-2010 REGN should be running large Eylea high-dose P3 (AMD), so IF one Miljenko Zuanic-11/24/2019
2803event.webcasts.com Good info on alnylam/regn pipeline. About 3hrs in.Biotechwantabe-11/23/2019
2802I think after Q1 or Q2 of 2020 will be key to see how much NVS has penetrated EyFelix B-11/23/2019
2801Yup! PS: Drawings (Fig. 21, P#38)) indicate (rabbit eye experiment) at least 2-fMiljenko Zuanic-11/21/2019
2800Good timing! With GILD life-cycle management, I presume you were referring to TDewDiligence_on_SI-11/21/2019
2799High conc. Eylea patent application: appft.uspto.gov At 100mg/mL and up to 24w: Miljenko Zuanic-11/21/2019
2798CD28-superagonist (TGN1412), Tegenero disaster from 2006! what went wrong and ,Miljenko Zuanic-11/19/2019
2797Suddenly, and somehow, REGN may advance as leader in IO (with CD28 co-stimulatioMiljenko Zuanic-11/19/2019
2796I think you should be interested to listen this Yan presentation on immunology aMiljenko Zuanic-11/18/2019
2795RE:KOD Kodiak S. continue with strong up-trajectory. Per 3Qcc, their plan for 3Miljenko Zuanic-11/15/2019
2794Samsung probably got into biosimilar manufacturing by tracking the communicationCuttingEdge Bio-11/12/2019
2793Typo correction: The sentence in parentheses should have said, “Lucentis is easyDewDiligence_on_SI-11/11/2019
2792<In my experience, biotech executives of companies whose drugs are being copiMiljenko Zuanic-11/11/2019
2791Inasmuch as BIIB is paying Samsung $100M in up-front cash, BIIB must be pretty cDewDiligence_on_SI-11/10/2019
2790I will continue to believe, until prove opposite, that Eylea manufacturing (fromMiljenko Zuanic-11/10/2019
2789Eylea-biosimilar transaction: investorshub.advfn.comDewDiligence_on_SI-11/9/2019
2788Eylea v Beovu Per CMS Part B dashboard spending (2017): portal.cms.gov BMiljenko Zuanic-11/7/2019
2787My memory is running short (I am older not younger), was that trial modified inMiljenko Zuanic-11/7/2019
2786RE: anti-CTLA4 IO contribution to 1L NSCLC, is there any space left? Early enthuMiljenko Zuanic-11/7/2019
2785It would seem that in all the haste to pare down their clinical program and satiCuttingEdge Bio-11/7/2019
2784When each arm have similar ORR and close mPFS, "duration" of treatmentMiljenko Zuanic-11/7/2019
2783ORR together with durationof response is indeed a good predictor of OS for I-O rDewDiligence_on_SI-11/7/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News